Treatment with the investigational drug crizanlizumab (SEG101) reduced pain in patients with sickle cell disease (SCD) who were experiencing vaso-occlusive crisis according to posthoc results of the phase II SUSTAIN study published online in The American Journal of Hematology. The study found that more than twice as many patients with SCD treated with crizanlizumab did not experience a VOC compared with those treated with placebo.
Treatment with the investigational drug crizanlizumab (SEG101) reduced pain in patients with sickle cell disease (SCD) who were experiencing vaso-occlusive crisis (VOC), according to posthoc results of the phase II SUSTAIN study, published online in The American Journal of Hematology.1 The study found that more than twice as many patients with SCD treated with crizanlizumab did not experience a VOC compared with those treated with placebo (35.8% vs 16.9%).
Crizanlizumab was shown to prevent VOCs in patients with 2 to 4 events in the year leading up to the study initiation. The drug prevented VOC events for 17 of 42 patients in the treated arm of the study and also prevented VOCs in patients with between 5 and 10 events in the year leading up to the study intervention, working for 7 of 25 patients in the treatment group and only 1 of 24 in the placebo group.
Crizanlizumab binds with P-selectin on the surface of endothelial cells and platelets in blood vessels, causing a blockage of P-selectin, which is one of the major drivers of the vaso-occlusive process. Novartis, the developer, expects to file a New Drug Application for the drug with the FDA in 2019.
VOC is the most common and painful complication among patients with SCD, and the main reason for these patients to be hospitalized for treatment. VOCs, which are triggered by multicell adhesion, are also associated with increased morbidity and mortality and can result in stroke, organ damage, or failure. There are few treatment options for VOC to date.
The SUSTAIN trial was a multicenter, multinational, randomized, placebo-controlled, double-blind 12-month study to assess safety and efficacy of crizanlizumab, with or without the concomitant use of hydroxyurea therapy in patients with SCD who have sickle-cell related pain crises. The primary results of SUSTAIN were published in The New England Journal of Medicine2 in 2017 and showed that crizanlizumab reduced the median annual rate of sickle cell pain crises by 45.4% compared with placebo (1.64 vs 2.98; P = .10) in patients with or without hydroxyurea therapy.
In the current posthoc analysis of the SUSTAIN study data, researchers analyzed data from 132 patients to determine the annual rate of VOC in patients who were treated with crizanlizumab compared with placebo. A total of 67 patients received crizanlizumab (5 mg/kg) and 65 received placebo. Each patient enrolled in the study had experienced at least 2 VOCs in the 12 months prior to study initiation. A total of 83 patients experienced between 2 and 4 VOC events, and 49 experienced between 5 and 10 VOCs. Most patients in the study (71.2%) had homozygous hemoglobin S subtype (HbSS) of disease, the most common SCD type. These patients were evenly split among the study cohorts. The remaining study subjects were classified as non-HbSS patients.
No new safety concerns emerged from the analysis; adverse events attributable to treatment were similar between the crizanlizumab and placebo arms across all subgroups. Adverse events that occurred in 10% or more patients in either the active treatment group or at a frequency that was at least twice as high as that in the placebo group were arthralgia, diarrhea, pruritis, vomiting, and chest pain. There were no apparent increases in infections with crizanlizumab treatment.
The study’s findings suggest that if approved by the FDA, crizanlizumab may become an important new therapeutic option for SCD. The investigators said they were encouraged that results from this analysis of SUSTAIN study data found that crizanlizumab could substantially delay or prevent these crises, which may also mean less organ damage in the long run.
References
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen